BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 35347894)

  • 1. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
    Jiang Y; Wang K; Lu X; Wang Y; Chen J
    Mol Immunol; 2021 Dec; 140():47-58. PubMed ID: 34653794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
    Yu F; Liang M; Huang Y; Wu W; Zheng B; Chen C
    J Exp Clin Cancer Res; 2021 Jun; 40(1):179. PubMed ID: 34074322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
    Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
    FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of bioinformatics analysis and experimental validation identifies plasma exosomal miR-103b/877-5p/29c-5p as diagnostic biomarkers for early lung adenocarcinoma.
    Wu J; Feng Z; Wang R; Li A; Wang H; He X; Shen Z
    Cancer Med; 2022 Dec; 11(23):4411-4421. PubMed ID: 35585716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal microRNA-26b-5p down-regulates ATF2 to enhance radiosensitivity of lung adenocarcinoma cells.
    Han F; Huang D; Huang X; Wang W; Yang S; Chen S
    J Cell Mol Med; 2020 Jul; 24(14):7730-7742. PubMed ID: 32476275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
    Jiang K; Zou H
    Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum exosomal miR-7977 as a novel biomarker for lung adenocarcinoma.
    Chen L; Cao P; Huang C; Wu Q; Chen S; Chen F
    J Cell Biochem; 2020 Jun; 121(5-6):3382-3391. PubMed ID: 31898829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-related exosomal circ_0001715 promotes lung adenocarcinoma cell proliferation and metastasis via enhancing M2 macrophage polarization by regulating triggering receptor expressed on myeloid cells-2.
    Chen M; Cao C; Ma J
    Thorac Cancer; 2024 Jan; 15(3):227-238. PubMed ID: 38087801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2 macrophage-derived exosomal miR-1911-5p promotes cell migration and invasion in lung adenocarcinoma by down-regulating CELF2 -activated ZBTB4 expression.
    Guan B; Dai X; Zhu Y; Geng Q
    Anticancer Drugs; 2023 Feb; 34(2):238-247. PubMed ID: 36730375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
    Lin J; Qiu Y; Zheng X; Dai Y; Xu T
    BMC Cancer; 2022 Jul; 22(1):756. PubMed ID: 35818041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial cell-derived exosomal miR-30a-5p inhibits lung adenocarcinoma malignant progression by targeting CCNE2.
    Tao K; Liu J; Liang J; Xu X; Xu L; Mao W
    Carcinogenesis; 2021 Aug; 42(8):1056-1067. PubMed ID: 34128973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
    Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
    Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.